SCHEMBL10248635

SCHEMBL10248635

CC(=O)c1ccc(N2CN(c3ccccc3)C3(CCN(C(=O)OCc4ccccc4)CC3)C2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 7/20 0.50
HTR1A P08908 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
HTR2C P28335 1/20 0.49
SLC6A3 Q01959 1/20 0.49
DDR1 Q08345 4/20 0.47
OPRM1 P35372 3/20 0.47
OPRD1 P41143 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
DRD5 P21918 1/20 0.46
AVPR1A P37288 1/20 0.45
BDKRB2 P30411 1/20 0.44
NPC1L1 Q9UHC9 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ENPP2 Q13822 1/20 0.42
ATXN2 Q99700 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL319477 0.92 OPRK1 (0.52) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL318654 0.90 OPRK1 (0.49) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL10248748 0.90 OPRK1 (0.51) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL318160 0.88 NPC1L1 (0.51) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL18601780 0.86 OPRK1 (0.50) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL10248761 0.85 OPRK1 (0.49) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL320115 0.83 OPRK1 (0.50) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL318917 0.81 OPRK1 (0.51) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL319441 0.81 OPRK1 (0.49) OPRK1HTR1AADORA3HTR2CSLC6A3
SCHEMBL318479 0.79 NPC1L1 (0.47) OPRK1HTR1AADORA3HTR2CSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156840-B2 D2 antagonists, methods of synthesis and methods of use Altos Therapeutics, LLC (US) 2015-10-13 US disclosed
US-20140350005-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-27 US disclosed
US-8691836-B2 D2 antagonists, methods of synthesis and methods of use Altos Therapeutics, LLC (US) 2014-04-08 US disclosed
US-20120010228-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE Altos Therapeutics, LLC 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350005-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE DRD2, DRD3, AVPR2 OPRK1 29/4885HTR1A 123/4885ADORA3 21/4885
US-20120010228-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE DRD2, DRD3, AVPR2 OPRK1 29/4885HTR1A 123/4885ADORA3 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.